Medline Inc. Class A Common Stock (MDLN)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)
MDLN
Medline Inc. Class A Common Stock
$42.67
+1.52%
HEALTHCARE · Cap: $34.68B
NNNN
Anbio Biotechnology Class A Ordinary Shares
$23.76
+2.46%
HEALTHCARE · Cap: $1.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 410755% more annual revenue ($28.43B vs $6.92M). NNNN leads profitability with a 37.2% profit margin vs 4.1%. MDLN trades at a lower P/E of 29.9x. MDLN earns a higher WallStSmart Score of 52/100 (C-).
MDLN
Buy52
out of 100
Grade: C-
NNNN
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.7%
Fair Value
$66.92
Current Price
$42.67
$24.25 discount
Margin of Safety
-3894.1%
Fair Value
$0.68
Current Price
$23.76
$23.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 73.5%
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
ROE of 6.5% — below average capital efficiency
4.1% margin — thin
Negative free cash flow — burning cash
2.8% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 37.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : MDLN
Revenue growth of 14.8% demonstrates continued momentum.
Bull Case : NNNN
The strongest argument for NNNN centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 37.2% and operating margin at 73.5%.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.
Bear Case : NNNN
The primary concerns for NNNN are EPS Growth, Market Cap, P/E Ratio. A P/E of 386.5x leaves little room for execution misses.
Key Dynamics to Monitor
MDLN profiles as a value stock while NNNN is a declining play — different risk/reward profiles.
MDLN is growing revenue faster at 14.8% — sustainability is the question.
NNNN generates stronger free cash flow (2M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (52/100 vs 37/100) and 14.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Anbio Biotechnology Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?